文献库搜索 | GeneLibs

Ashour(AM),Alhayyan(A),Alhayyan(R) Medicine (Baltimore) 2026-08-14

...BRCA1/2, and Epidermal Growth Factor Receptor. Breast cancer, colorectal cancer, and non-small cell lung cancer were amo...

Cao(Y),Lewis(Y),Tu(L),Alesi(LR),Stringer(J... Reprod Biomed Online 2026-07-24

...Brca1 deletion [conditional knockout (cKO): Brca1fl/flGdf9cre/+] and wild-type controls (Brca1fl/flGdf9+/+). Young (40-8...

Durán-Toribio(AK),Jiménez-Díaz(IF),Caballé... Crit Rev Oncol Hematol 2026-08-15

...BRCA1, and XRCC4/5/6 correlates with poor survival in non-small cell lung cancer, whereas low ERCC1 expression and speci...

Yuan(Y),Zhang(L),Liao(J),Wang(B),Lu(L),Chu... Clin Transl Med 2026-08-00

...BRCA1 variants, raising the possibility that SMMN-FGT may be part of a broader BRCA1-associated phenotypic spectrum. Som...

Stracke(C),Kautz-Freimuth(S),Shukri(A),Iss... PLoS One None

Women with BRCA1/2 pathogenic variants (PVs) without a personal cancer history and with open family planning are in a ve...

Xu(Y),Lei(Q),Yang(S),Zhang(Y),Luo(X),Song(... Eur J Med Chem 2026-08-16

...BRCA1, BRCA2 and RAD51, thereby triggering enhanced DNA damage and cell apoptosis. Notably, in the BRCA wild-type MDA-MB...

Zhu(H),Fang(Y),Yang(M),Gao(T),Zhou(Y),Zhao... Transl Oncol 2026-08-17

...BRCA1 was selected for functional validation. Consistent with the bioinformatic analyses, BRCA1 was markedly upregulated...

Incorvaia(L),Santini(D),Matrana(MR),Maruzz... Int J Cancer 2026-08-18

...BRCA1/2 vs. non-BRCA HRR: 16.3 months [95% CI, 13.0-69.6] vs. 14.2 [95% CI, 12.0-22.9; p = 0.681]). Primary refractorine...

Reinert(T),Alshehri(AS),Shafik(A),Lin(CH),... Ther Adv Med Oncol None

...BRCA1/2 or PALB2 testing, while ctDNA is preferred for ESR1 detection. Next-generation sequencing (NGS) is the preferred...

Ruci(A),Smart(C) Cureus 2026-07-00

...BRCA1)/ataxia-telangiectasia mutated (ATM) mutations and invasive lobular carcinoma of the left breast status post bilat...